Aerovate Therapeutics (NASDAQ:AVTE) Issues Quarterly Earnings Results

Aerovate Therapeutics (NASDAQ:AVTE) posted its quarterly earnings data on Thursday. The company reported ($0.19) EPS for the quarter, hitting analysts’ consensus estimates of ($0.19), Zacks reports.

Aerovate Therapeutics Stock Down 0.4 %

Shares of AVTE stock traded down $0.01 during trading on Friday, reaching $2.52. 2,094 shares of the company’s stock were exchanged, compared to its average volume of 572,417. Aerovate Therapeutics has a twelve month low of $1.25 and a twelve month high of $32.42. The firm’s fifty day moving average price is $2.50 and its 200-day moving average price is $2.43. The stock has a market capitalization of $72.77 million, a PE ratio of -0.84 and a beta of 1.01.

Aerovate Therapeutics Company Profile

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.